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Abstract
Introduction: Cytochrome P-450 2E1 (CYP2E1) is an important member of the CYP superfamily, which is involved
in the metabolism and activation of many low molecular weight toxic compounds. We tried to investigate the
possible association of CYP2E1 tag single nucleotide polymorphisms (SNPs) with susceptibility to systemic lupus
erythematosus (SLE) in a Chinese Han population.
Methods: The coding and flanking regions of the CYP2E1 gene were scanned for polymorphisms and tag SNPs
were selected. A two-stage case-control study was performed to genotype a total of 876 SLE patients and 680
geographically matched healthy controls (265 cases and 288 controls in stage I and 611 cases and 392 controls in
stage II). SLE associations of alleles, genotypes and haplotypes were tested by age and sex adjusted logistic
regression. The gene transcription quantitation was carried out for peripheral blood mononuclear cell (PBMC)
samples from 120 healthy controls.
Results: Tag SNP rs2480256 was found significantly associated with SLE in both stages of the study. The “A” allele
was associated with slightly higher risk (odds ratio (OR) = 1.165, 95% confidence interval (CI) 1.073 to 1.265, P = 2.75E-
4) and “A/A” genotype carriers were with even higher SLE risk (OR = 1.464 95% CI 1.259 to 1.702, P = 7.48E-7). When
combined with another tag SNP rs8192772, we identified haplotype “rs8192772-rs2480256/TA” over presented in SLE
patients (OR 1.407, 95% CI 1.182 to 1.675, P = 0.0001) and haplotype “TG” over presented in the controls (OR 0.771,
95% CI 0.667 to 0.890, P = 0.0004). The gene transcription quantitation analysis further proved the dominant effect of
rs2480256 as the “A/A” genotype showed highest transcription.
Conclusions: Our results suggest the involvement of CYP2E1 as a susceptibility gene for SLE in the Chinese
population.
Introduction
Systemic lupus erythematosus (SLE (OMIM 152700)) is a
chronic autoimmune disease with heterogeneous clinical
features ranging from mild forms to progressive end organ
damage. It is characterized by humoral and cellular immu-
nity to self antigens. Approximately 90% of SLE patients
are female. Epidemiological studies suggest the contribu-
tion of multiple factors including genetics, environmental
exposure and gene-environmental interactions in the
etiology of SLE [1-4] The significant difference of SLE pre-
valence between African descents in industrialized coun-
tries and residents in West African countries [5] suggested
the combined effects of genetic basis and environmental
effect(s) for the clinical manifestation of SLE. Potential
environmental triggers for SLE include radiation and
exposure to a wide range of exogenous and endogenous
xenobiotic compounds [6,7]. Exposure to trichloroethylene
(TCE), a volatile organic solvent, was found in several epi-
demiological studies to induce SLE and some other auto-
immune diseases such as scleroderma [8,9]. Autoimmune
effects including activation of CD4+ T-cells and an
increase of autoantibodies were detected in MRL+/+ mice
subjected to TCE exposure [10-12]. Recently, silica
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associated with an increased risk of SLE [13].
The cytochrome P-450 enzymes (CYPs) are responsi-
ble for the oxidative metabolism and biotransformation
of a variety of substrates. The marked inter-individual
variability in the expression of CYP genes contributes to
t h ed i f f e r e n c ei nt h ed i s p o s i t i o no fm a n ye n d o -a n d
xeno-biotics, including the metabolites of steroids, envir-
onmental toxins and therapeutics [14]. CYP2E1, an
important member of CYP superfamily, is involved in
the metabolism and activation of many low molecular
weight toxic compounds, including ethanol, benzene,
nitrosamine and TCE [15]. In MRL +/+ mice, inhibition
of CYP2E1 reversed immune-related effects induced by
TCE [16]. We undertook this study to evaluate any
association between CYP2E1 genetic polymorphisms
and SLE in a Chinese study population.
Materials and methods
Subjects and study strategy
A total of 876 patients with SLE (89% female, mean age
24.9 ± 9.9 years) and 680 healthy individuals (58%
female, mean age 51.0 ± 17.6 years) were recruited in
the present two-stage study from July 2004 to Septem-
ber 2006 (the first stage) and from October 2006 to
August 2007 (the second stage). Unrelated Chinese sub-
jects with SLE according to the American College of
Rheumatology (ACR) 1982 revised criteria for the classi-
fication of SLE [17] were recruited from multiple medi-
cal centers in Zhejiang, Shangdong and Liaoning
provinces. All medical records were reviewed to confirm
the patient’s eligibility and to gather relevant clinical
data at the time of diagnosis. Clinical features of the dis-
ease were recorded in standardized questionnaires and
written informed consent from each participant was also
received. The clinical and immunological features of the
SLE patients are shown in Supplementary Table S1 in
Additional file 1. The controls are area-matched unre-
lated healthy individuals visiting hospitals. Sample hand-
ling and confidentiality protection strictly adhered to the
protocols approved by Ethics Committee of The Hong
Kong University of Science and Technology. Genomic
DNA was extracted from EDTA-treated whole blood
using the GFX™ Genomic Blood DNA Purification Kit
(Amersham Biosciences, Piscataway, NJ, USA).
In this study, we first screened CYP2E1 gene poly-
morphisms in a panel of 96 healthy individuals. Then
the association study for tag SNPs and haplotypes was
carried out in a two-stage study approach. During the
stage I study, we recruited and genotyped 265 SLE cases
(86% female) and 288 controls (81% female) to identify
SLE associated SNPs and haploty pes. For the stage II
study, we recruited and genotyped 611 SLE patients
(90% female) and 392 healthy controls (48% female).
CYP2E1 sequence variations screening and tag SNP
selection
For the sequence variation screening the CYP2E1 gene
region was amplified as eight polymerase chain reaction
(PCR) fragments covering a total of 7.5 kb, including
the promoter region, exons, exon-intron junctions, as
well as the 5’ and 3’ untranslated regions. Supplemen-
tary Table S2 in Additional file 1 shows the primer
sequences and PCR conditions used in this study. Direct
DNA sequencing was employed to identify the sequence
variations. PCRs were performed using hot-start Ampli-
Taq
® Gold DNA polymerase kit (Applied Biosystems,
Foster City, CA, USA) and a MJ PTC-200 (Bio-Rad,
Hercules, CA, USA) thermal cycler. PCR reaction was
carried out in 20 μl solution containing 1.5 mM Mg
2+,
200 μMd N T P ,0 . 3μM each primer, 10 ng genomic
DNA as template, and 0.5 U polymerase. Five percent
DMSO is included in the PCR reaction mixture, particu-
larly for the amplification of exon 2 and exon 9. After
confirming the purity and mobility by agarose gel elec-
trophoresis, each PCR product was purified and sub-
jected to DNA sequencing using BigDye
® Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster
City, CA, USA) and the ABI Prism
® 3100 Genetic Ana-
lyzer (Applied Biosystems, Foster City, CA, USA). Each
sample was sequenced for both strands to confirm the
r e s u l t sa n dt h eS N P sw e r ei d e n t i f i e db yu s i n gS e q S c a p e
(ABI, Foster City, CA, USA).
Genotyping for tag SNPs rs8192772, rs2070672 and
rs2480256 in stage I and II were performed using direct
sequencing described above, while tag SNP rs2031920
was detected using previously described Restriction
Fragment Length Polymorphism methods [18].
Statistical analysis
The Hardy-Weinberg equilibrium test was done for each
polymorphism detected in the control population. The
software HaploView 3.32 (Massachusetts Institute of
Technology, Cambridge, MA, USA) [19] was used to
calculate linkage disequilibrium (LD) and software
PHASE v 2.1 (Department of Statistics, University of
Chicago, Chicago, IL, USA) [20] was used for inferring
haplotypes as well as analyzing haplotype association.
Tag SNPs were selected using Carlson’sm e t h o d[ 2 1 ] .
Using this method, bins of the common SNPs that are
in very strong LD with a specified r
2 threshold were
identified and then one SNP was selected to represent
the remaining SNPs in each bin. We used an r
2 thresh-
old of 0.8 and a minimum minor allele frequency of
0.05. When multiple SNPs were assigned as tag SNPs
for a particular bin, the SNP was selected for that bin
based on LD pattern, ease of assay design and probabil-
ity of being functionally important. The alleles and gen-
otypes of the SNPs were counted, and their distributions
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the c
2 test to test the hypothesis of association between
polymorphism and SLE. Considering the multiple tests
involved in this study, a P-value < 0.01 was set as signif-
icant level. The P-value and odd ratios (OR) with 95%
confidence intervals (CI) were estimated using condi-
tional logistic regression models adjusted for potential
confounders. All the analysis was performed with pro-
gram SPSS 12.0 (SPSS Inc., Chicago, IL, USA).
CYP2E1 transcription quantification
One hundred and twenty healthy individuals were
assessed for the CYP2E1 mRNA levels in peripheral
blood. The QuantiGene
® assay (Affymetrix Inc., Santa
Clara, CA, USA) was used to quantify the mRNA con-
sidering the accuracy and precision of this technology
without RNA purification and RT-PCR [22,23]. Accord-
ing to the manufacture’s design and instruction, 10 ul
EDTA anti-coagulant blood was lysed at the day of col-
lection. Blood lysates and specific probe sets were incu-
bated in the capture plate and hybridized overnight at
55°C. Pre-amplifier and amplifier reagents were incu-
bated in the capture plate for 60 minutes at 55°C fol-
lowed by 50°C incubation of label probe with washing
between each incubation. Substrate reagents were added
in the end and plates were read on a chemiluminescent
plate reader. The CYP2E1 signal was normalized to an
averaged signal from two reference genes GAPDH and
ACTB. All participants were genotyped by sequencing
for SNPs rs8192772 and rs2480256. ANOVA test (SPSS
12.0) was used to compare the normalized transcription
level among different genotype groups.
Results
Sequence variations in the CYP2E1 gene
A total of 32 sequence polymorphisms (minor allele fre-
quency MAF >/= 1%) were identified in 96 healthy con-
trol samples (12 in the putative promoter region, 2 in
the coding region, 16 in the introns and 2 in the 3’
UTR). Genotypes were in Hardy-Weinberg equilibrium
at each polymorphic locus. Supplementary Table S3 in
A d d i t i o n a lf i l e1a n dF i g u r e1s h o w st h el o c a t i o na n d
frequency of these SNPs. Thirty of them were previously
reported in the dbSNP [24] and in the literature
[18,25,26], whereas the -1381C/T and -760T/G were
newly identified in our study. A high density of SNPs
was observed in the putative promoter region, where 12
SNPs were identified within 1.8 kb sequence. Compared
Figure 1 LD structure of CYP2E1 gene region in Chinese population. LD structure is determined by using the confidence intervals option of
Haploview. D prime values are displayed in the squares (values of 1.0 are not shown). Square background colors showed the pairwise r
2 value
(r
2 = 1 for black color and gradually coloring down to white as r
2 = 0).
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regions, the frequency of variations in the coding region
is relatively low. Only two synonymous variations,
rs28371746 and rs2515641, were detected in exon 6 and
exon 8 respectively. We excluded five rare SNPs with
MAF less than 5% from LD analysis, haplotype recon-
struction and association analysis because rare alleles do
not have sufficient statistic power [27,28].
Tag SNP selection
Pairwise LD across the CYP2E1 gene (Figure 1) was rela-
tively strong in this Chinese population and without clear
LD block subdivision. All the 27 common SNPs were clas-
sified into four bins using Carlson’s method [21]. Four tag
SNPs, rs2031920, rs2070672, rs8192772 and rs2480256,
were selected from each bin for further study based on
their allele frequencies, LD pattern and probability of
being functionally important. The rs2031920 and
rs2070672 were located in the promoter region, rs8192772
was in the intron 2 and rs2480256 was in the 3’UTR.
Stage I: association of tag SNPs and haplotypes with SLE
In stage I, we recruited 265 SLE patients and 288 controls
for genotyping the four tag SNPs. Table 1 showed the
distribution of both allele and genotype frequencies of
the case and control groups. Association analysis revealed
that two tag SNPs were associated with SLE. For tag SNP
rs8192772, frequency of “C/C” genotype in cases (5.3%)
was almost two-fold higher than in the control (1.7%).
Therefore, at genotypic level the homozygous “C/C” gen-
otype was associated with elevated risk of SLE compared
with T/T and T/C carriers (OR = 1.912, 95% CI 1.131 to
3.324, P = 0.016). In the case of tag SNP rs2480256, asso-
ciation analysis at both allelic and genotypic levels sug-
gested that this SNP contributes to the susceptibility of
SLE. The frequency of “A/A” genotype was significantly
higher in SLE patients (22.6%) than in the healthy con-
trols (11.8%). The “A/A” genotype carriers have signifi-
cantly elevated risk of SLE compared with “G/G” and “A/
G” carriers (OR = 1.475, 95% CI 1.170 to 1.860, P =
0.001). At allelic level, a marginal association was found
Table 1 Association analysis of four tag SNPs and haplotypes with SLE in the stage I study
No.
SNP Controls Cases Crude OR (95% CI) Crude P Adjusted OR (95% CI) Adjusted P
rs2031920
allelic C 462 401 1.081 (0.804 to 1.454) 0.604 1.029 (0.887 to 1.195) 0.703
T 114 107
geonotypic C/C+C/T 184 + 94 159 + 83 1.379 (0.585 to 3.247) 0.461 1.151 (0.749 to 0.176) 0.52
T/T 10 12
rs2070672
allelic A 480 430 0.907 (0.655 to 1.256) 0.557 0.968 (0.821 to 1.142) 0.701
G9 6 7 8
geonotypic A/A+G/G 199 + 7 186 + 10 0.743 (0.504 to 1.096) 0.135 0.753 (0.508 to 1.115) 0.156
A/G 82 58
rs8192772
allelic T 454 426 0.913 (0.681 to 1.224) 0.542 0.970 (0.837 to 1.125) 0.686
C 122 102
geonotypic T/T + T/C 171 + 112 174 + 76 3.170 (1.126 to 8.925) 0.022 1.912 (1.131 to 3.234) 0.016
C/C 5 14
rs2480256
allelic G 360 295 1.282 (1.007 to 1.633) 0.043 1.128 (0.999 to 1.274) 0.053
A 216 223
geonotypic G/G+G/A 106 + 148 93 + 109 2.182 (1.377 to 3.459) 0.001 1.475 (1.170 to 1.860) 0.001
A/A 34 59
Haplotype (rs2031920-
rs2070672-rs8192772-
rs2480256)
Frequency in the
Control
Frequency in
the SLE
OR (95% CI) P-value
CATG 58.50% 54.70% 0.856 (0.674 to 1.088) 0.205
TATA 15.70% 19.70% 1.321 (0.967 to
1.803)
0.081
CGCA 15.90% 14.50% 0.896 (0.644 to 1.247) 0.513
Combination of rare haplotypes
(frequency <5%)
9.90% 11.10%
CI, confidence interval; OR, odds ratio; SLE, systemic lupus erythematosis; SNP, single nucleotide polymorphism.
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(OR = 1.128, 95% CI 0.999 to 1.274, P = 0.053).
The common haplotypes and their frequency in the
patients and controls inferred from PHASE program
were listed in the Table 1. Only three haplotypes were
presented with frequency greater than 0.05 and all the
other minor haplotypes were combined for association
study. The frequency of haplotype “TATA” in SLE
patients is higher than that in the controls and revealed
am a r g i n a la s s o c i a t i o n( P = 0.081). Since this haplotype
“TATA” could be identified from other common haplo-
types by genotyping SNPs rs8192772 and rs2480256, we
then only genotyped these two haplotype tag SNPs in
stage II study with enlarged sample pool.
Stage II: verifying the association of tag SNPs rs8192772
and rs2480256 with SLE
During the stage II study, we recruited another 611 SLE
patients and 392 controls for the genotyping of SNPs
rs8192772 and rs2480256. The result confirmed the asso-
ciation tendency revealed in the stage I study (Table 2).
For SNP rs8192772, the frequency of “C/C” genotype is
higher in the SLE patients than in controls (OR = 1.433,
95% CI 1.023 to 2.009, P = 0.037). For SNP rs2480256,
both “A” allele (OR = 1.115, 95% CI 1.016 to 1.223, P =
0.022) and “A/A” genotype (OR = 1.256, 95% CI 1.062 to
1.485, P = 0.008) are associated with SLE.
When all genotyping data from both stage I and II stu-
dies were combined (Table 2), tag SNP rs8192772 was
associated with SLE at genotypic level and the “C/C” car-
rier showed a 1.820-fold increase in SLE risk (95% CI
1.33 to 2.49 P = 1.08E-4). For tag SNP rs2480256, it asso-
ciated with SLE at both allelic and genotypic level. The
“A” allele was associated with slightly higher risk (OR =
1.165, 95% CI 1.073 to 1.265, P = 2.75E-4) and “A/A”
genotype carriers were with even higher SLE risk (OR =
1.464, 95% CI 1.259 to 1.702, P = 7.48E-7). Haplotypes
comprising tag SNPs rs8192772 and rs2480256 and their
frequencies in case and controls were also estimated.
Three haplotypes were observed with frequency higher
than 5% (Table 2). The frequency of haplotype “TA” was
24.5% in SLE patients, compared with 18.8% in controls
(OR = 1.407, 95% CI 1.182 to 1.675, P = 0.0001). In con-
trast, haplotype “TG” is more common in the controls
(60.4%) than in the patients (54.0%) (OR = 0.771, 95% CI
0.667 to 0.890, P = 0.0004). We also analyzed the associa-
tion between SNP genotypes and various clinical features
adjusted by both sex and age. However, no genotype cor-
relation with any clinical feature was identified.
Transcription quantification of CYP2E1 in PBMC
In order to study the effect of rs2480256 on CYP2E1 gene
expression, we further recruited 120 healthy individuals to
explore the CYP2E1 mRNA level in PBMC. By sequencing
genotyping of these 120 individuals, 22 were found as “A/
A” genotype, 45 were “G/G” and 53 were heterozygous
“G/A”. As shown in Figure 2A, the normalized relative
mRNA levels from genotype “A/A”, “G/G” and “G/A”
were 2.01(95% CI 1.79 to 2.23), 1.59 (95% CI 1.43 to 1.76)
and 1.74 (95% CI 1.62 to 1.86) respectively. The multiple
group test showed the transcription levels among these
three groups were significant different (P-value = 0.006).
The risky genotype “A/A” showed the highest transcrip-
tion while the lowest is genotype “G/G”.W ea l s og e n o -
typed SNP rs8192772 and analyzed the transcription
difference in different genotypes (Figure 2B). Only “C/C”
(2.35, 95% CI 1.68 to 3.03) genotype showed significant
higher transcription (P < 0.05) comparing to the other two
genotypes. The transcription levels between “T/T” (1.78,
95% CI 1.65 to 1.91) and “T/C” (1.60, 95% CI 1.47 to 1.73)
genotype did not show statistical significant difference.
Discussion
After conducting a two-stage study involving the geno-
typing and clinical evaluation of 876 SLE patients and
680 healthy controls recruited among Han Chinese, we
provide the first time evidence for the statistically signif-
icant association for SNP rs2480256, of CYP2E1 with
SLE. The “A/A” carriers for SNP rs2480256 showed
higher SLE risk (OR = 1.464 95% CI 1.259 to 1.702, P =
7.48E-7). We also detected that haplotype “rs8192772-
rs2480256/TG” was overrepresented in controls (OR =
0.771, 95% CI 0.667 to 0.890, P = 0.0004) whereas hap-
lotype “TA” was overrepresented in SLE patients (OR =
1.407, 95% CI 1.182 to 1.675, P = 0.0001). Though the
“C/C” genotype of rs8192772 showed a 1.820-fold higher
S L Er i s k( 9 5 %C I1 . 3 3t o2 . 4 9 ,P = 1.08E-4), the haplo-
type analysis suggested the dominant effect of SNP
rs2480256 in SLE susceptibility.
SNP rs2480256 is located in the 3’ UTR, a region with
proven role(s) in the regulation of gene expression.
Many disease-associated variants have been mapped in
the 3’ UTR of human protein-coding genes [29]. A
recent publication on SLE susceptibility exploring also
revealed a significant association of a variation located
in 3’UTR of ETS1 gene [30,31]. The significant associa-
tion of SNP rs2480256 to SLE maybe due to its effect
on CYP2E1 gene expression and/or its LD with a func-
tional variant residing in either CYP2E1 or neighboring
g e n e s .I no r d e rt oc l a r i f yw h e t h e rt h i sS N Pc a na f f e c t
the CYP2E1 transcription, we examined the CYP2E1
mRNA level in PBMC sample collected from individuals
with different genotype. The statistical analysis showed
that CYP2E1 mRNA levels are significantly different
among different rs2480256 genotypes. The most risky
genotype “A/A” showed highest transcription levels,
while the protective genotype “G/G” is the lowest. It is
also interesting that, for SNP rs8192772, the only risky
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scription but not “T/C” heterozygous. By examining the
LD between these two SNPs, we noticed that only the C
allele of rs8192772 is in very strong LD with the A allele
of rs2480256 (D’ = 1). This explained why the rs8192772
“C/C” genotype showed higher CYP2E1 transcription
but not in the “C/T” genotype. This transcriptional ana-
lysis confirmed the genotyping haplotype analysis pro-
posed dominant effect of rs2480256.
Xenobiotic exposures often trigger the onset of auto-
immune diseases including SLE, human CYP genes have
significant bearing on individual susceptibility to chemi-
cal toxicity and were speculated to be involved in several
‘lupus-like’ disorders [32]. The inactive CYP2D6*4A
a l l e l em a yb eac o n t r i b u t o r yf a c t o rf o rS L E[ 3 3 ] .A f t e r
genotyping 90 SLE patients and 94 healthy controls, Yen
et al. [34] concluded that CYP1A1 4887A may be a pre-
cipitating factor for SLE, and they detected a synergistic
Table 2 Association analyses for rs8192772 and rs2480256 in stage II and the combined two stages
No.
SNP Controls Cases Crude OR (95%
CI)
Crude
P
Adjusted OR
(95% CI)
Adjusted
P
rs8192772
allelic T 621 925 1.105 (0.886 to
1.378)
0.375 1.057 (0.945 to
1.182)
0.331
C 161 265
geonotypic T/T+T/
C
242 + 137 365 + 195 1.973 (1.012 to
3.852)
0.043 1.433 (1.023 to
2.009)
0.037
C/C 12 35
Stage II
rs2480256
allelic G 467 641 1.231(1.025 to
1.480)
0.026 1.115 (1.016 to
1.223)
0.022
A 313 529
geonotypic G/G
+G/A
140 + 187 191 + 259 1.557 (1.118 to
2.169)
0.008 1.256 (1.062 to
1.485)
0.008
A/A 63 135
rs8192772
allelic T 1,075 1,348 1.039 (0.873 to
1.237)
0.667 1.045 (0.946 to
1.154)
0.384
C 283 368
geonotypic T/T+T/
C
413 + 249 539 + 271 2.356 (1.344 to
4.129)
0.002 1.820 (1.330 to
2.490)
1.81E-04
C/C 17 49
Stage I +
Stage II
rs2480256
allelic G 827 936 1.62 (1.092 to
1.460)
0.002 1.165 (1.073 to
1.265)
2.75E-04
A 529 756
geonotypic G/G
+G/A
246 + 335 284 + 368 1.782 (1.363 to
2.330)
2.07E-
05
1.464 (1.259 to
1.702)
7.48E-07
A/A 97 194
Haplotype rs8192772-
rs2480256
Frequency in the
Control
Frequency in the
SLE
OR (95% CI) P-
value
TG 60.36% 54.00% 0.771 (0.668 to
0.890)
0.0004
TA 18.75% 24.46% 1.407 (1.182 to
1.675)
0.0001
CA 20.14% 20.05% 0.994 (0.833 to
1.186)
0.944
CI, confidence interval; OR, odds ratio; SLE, systemic lupus erythematosis; SNP, single nucleotide polymorphism.
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and Mn SOD 1183T/T. Recent studies in Chinese and
Korean further identified Glutathione S-transferase
family and CYP1A1 are involved in SLE development
[35,36]. As a phase I enzyme, CYP2E1 encodes N,N-
dimethylnitrosamino N-demethylase which can catalyze
xenobiotics into a more reactive and toxic form. In
addition to its ability to metabolize a wide variety of low
molecular weight compounds, it is also an effective gen-
erator of reactive oxygen species (ROS) [37]. Among the
wide substrate spectrum of CYP2E1, TCE has been
implicated in the development of autoimmune disorders
and immune system dysfunction both in human and
animal studies [12,16,38]. TCE is a widely used indus-
trial solvent for degreasing and paint stripping. This
volatile organic compound is a common pollutant found
in soil and water. Recently, ROS and oxidative stress
were implicated in the pathogenesis of SLE [39]. It has
been demonstrated that DNA damaged by ROS is highly
immunogenic [40,41]. Therefore, it is possible that the
higher expression of CYP2E1 contributed to SLE devel-
opment through the production of more ROS during
the compound metabolization with/or particular toxic
intermediates produced, for example, metabolites of
TCE.
CYP2E1 is located in the chromosome 10q24.3-qter,
the gene spans over 11 kb and contains 9 exons. When
we started this project, the tag SNPs for CYP2E1 was
not available in the HAPMAP database and literature.
We were able to identify four tag SNPs (rs2031920,
rs2070672, rs8192772 and rs2480256) by pairwise LD
analysis for haplotype inferring. Such detailed informa-
tion is a good complementary to the released Phase III
Hapmap data. And by searching the most updated pub-
lic database, no other putative or known genes showed
significant LD with the SNP rs2480256. In recent years,
several genome-wide association studies have been con-
ducted to identify SLE susceptibility markers in different
ethnic groups, including the Chinese Han population
[31,42-46]. Though validity of these findings has been
shown in genes such as ETS1 and SLC15A4, people also
noticed that every study revealed some unique markers.
A n di nt h e s ep u b l i s h e dG e n o m eW i d eA s s o c i a t i o n
Study data, none of the susceptible markers has a physi-
cal linkage with the markers we identified in this study.
On the other hand, several genomic scans detecting SLE
predisposition genes were performed in extended multi-
case families or sib-pairs [47-54]. The few overlaps
detected among these studies indicate that multiple pre-
disposing genes, ethnic diversity, and genetic heteroge-
neity are likely. After conducting a 10-cM full genome
scan with approximately 400 multiallelic markers for
238 individuals from a multiethnic panel of 62 multiplex
SLE families, Cantor et al. [47] confirmed the linkage to
four previously reported sites (1q23, 2q33, 16q12 to 13
and 17q21 to 23) and revealed four novel sites (3p24,
10q23 to 24, 13q32 and 18q22 to 23). One of these
sites, 10q23 to 24, is very close to the CYP2E1 locus.
These projects exhibit the complexity of identifying sus-
ceptibility genes in a case-control study. The elucidation
of disease mechanism and the functional importance of
markers involved may eventually guide us to clinical and
therapeutic applications.
In this project, we adopted a two-stage association
study strategy. In the first stage, all tag SNPs were
screened and only the most promising markers were
then genotyped in the second stage in other samples.
Compared to one-stage designs, two-stage designs can
reduce the amount of genotyping and provide near-opti-
mal power to detect the true marker conferring disease
risk [55]. In conclusion, the present study suggests that
genetic variations in the CYP2E1 gene may contribute
to SLE susceptibility in the Chinese Han population.
One potential concern of the current study is that we
only tested limited variants in the functional region of
CYP2E1 gene and left a relatively large region of introns
unexplored, which is also not available in a chip-based
genotyping assay. It is possible that, by employing a
Figure 2 Relative transcription level of CYP2E1on SNP rs2480256 (A) and rs8192772 (B).
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Page 7 of 9denser marker map, we may observe some other signifi-
cantly associated markers which may be involved in reg-
ulating gene expression. In addition, replications in
other populations and further functional studies are also
required to confirm and interpret the association of
CYP2E1 gene with SLE.
Conclusions
CYP2E1 gene contributes to the SLE susceptibility in
Han Chinese population. The haplotype “rs8192772-
rs2480256/TG” was overrepresented in controls (OR
0.771, 95% CI 0.667 to 0.890, P = 0.0004), whereas hap-
lotype “TA” was overrepresented in SLE patients (OR =
1.407, 95% CI 1.182 to 1.675, P = 0.0001). SNP
rs2480256 showed the dominant effect by significantly
affecting the CYP2E1 transcription.
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